EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference
Rhea-AI Summary
EyePoint Pharmaceuticals (NASDAQ: EYPT), a leading developer of therapeutics for serious retinal diseases, has announced its upcoming participation in the 2025 RBC Capital Markets Ophthalmology Virtual Conference.
The company's President and CEO, Jay S. Duker, M.D., will engage in a fireside chat scheduled for April 4, 2025, at 10:00 a.m. ET. Investors and interested parties can access the live webcast and subsequent replay through the Investors section on EyePoint's website at www.eyepointpharma.com.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, EYPT declined 2.48%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
WATERTOWN, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint, will participate in a fireside chat at the 2025 RBC Capital Markets Ophthalmology Conference on Friday, April 4, 2025 at 10:00 a.m. ET.
A live webcast and subsequent archived replay of the fireside chat may be accessed via the Investors section of the Company website at www.eyepointpharma.com.
About EyePoint
EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery. The Company’s lead product candidate, DURAVYU™ is an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with bioerodible Durasert E™. Supported by robust safety and efficacy data to date, DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD), the leading cause of vision loss among people 50 years of age and older in the United States and recently completed a Phase 2 clinical trial in diabetic macular edema (DME). Based on positive Phase 2 results from the VERONA clinical trial in DME, EyePoint anticipates meeting with U.S. and ex-U.S. regulatory agencies in the second quarter of 2025 to confirm plans for a pivotal program.
Pipeline programs include EYP-2301, a TIE-2 agonist, razuprotafib, formulated in Durasert E™ to potentially improve outcomes in serious retinal diseases. The proven Durasert® drug delivery technology has been safely administered to thousands of patient eyes across four U.S. FDA approved products in multiple disease indications. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
Investors:
Christina Tartaglia
Precision AQ
Direct: 212-698-8700
christina.tartaglia@precisionaq.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
When is EyePoint Pharmaceuticals (EYPT) presenting at the RBC Capital Markets Conference 2025?
Who will represent EYPT at the 2025 RBC Capital Markets Ophthalmology Conference?
How can investors watch EyePoint's (EYPT) presentation at the RBC Conference?
What is the main focus of EyePoint Pharmaceuticals' (EYPT) business?
